Trial – AMGEN/IQVIA

Suffering from Chronic Hives?

A 32-week Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of xxxxxxxxxx for the Treatment of Chronic Spontaneous Urticaria

Males and Females between the ages of 18-80 may qualify.

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol # 20190194

Trial – Sun Pharma | IQVIA

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of XXXXXXXXX in the Treatment of Moderate to Severe Nail Psoriasis.

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol #TILD-18-19

This ICON/Trevi 1 year study aims to determine the evaluate the safety, tolerability, and effectiveness of nalbuphine as a treatment for the itching related to Prurigo Nodularis (PN). This study will also evaluate participant’s itch-related quality of life and sleep quality. There are currently no approved treatments specifically for people who experience itching due to Prurigo Nodularis.

To participate in your local study, please contact  (949) 844-0442 or fill out the form below.

Protocol # TR-11

Phase III Clinical Trial – Novartis

A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa

To participate in your local study, please contact  (949) 707-5734 or fill out the form below.

CAIN457M2302